RPTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Preferred stock is a special equity security that has properties of both equity and debt. Repare Therapeutics's preferred stock for the quarter that ended in Dec. 2023 was $0.00 Mil.
The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Repare Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $85.27 Mil.
In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Repare Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $5.03.
Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Repare Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.67.
The historical data trend for Repare Therapeutics's Preferred Stock can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repare Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Preferred Stock | Get a 7-Day Free Trial | - | - | - | - | - |
Repare Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Preferred Stock | Get a 7-Day Free Trial | - | - | - | - | - |
Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.
Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.
Preferred stock comes in many forms. It can be:
A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.
Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?
It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.
Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.
Repare Therapeutics (NAS:RPTX) Preferred Stock Explanation
When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.
For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffetts Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffetts Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?
1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.
Repare Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value | |||||||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation | + | Minority Interest |
= | 307.8848 | + | 0 | + | 1.01 | + | 0 | + | 0 |
- | Cash, Cash Equivalents, Marketable Securities | ||||||||
- | 223.627 | ||||||||
= | 85.27 |
2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.
Repare Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is calculated as
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (Diluted Average) |
= | (212.082 | - | 0) | / | 42.176 | |
= | 5.03 |
3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.
Repare Therapeutics's Earnings per Share (Diluted) (EPS) for the three months ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-28.03 | - | 0) | / | 42.140 | |
= | -0.67 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Repare Therapeutics's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Michael Zinda | officer: EVP, Chief Science Officer | C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1 |
Susan Molineaux | director | C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Davis Jerel | director, 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Ventures V, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Vantage I, L.p. | 10 percent owner | ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104 |
Thomas Civik | director | C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141 |
Mark N Lampert | 10 percent owner | 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
Biotechnology Value Fund Ii Lp | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Inc/il | 10 percent owner | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Biotechnology Value Trading Fund Os Lp | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Bvf Partners Os Ltd. | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Bvf Partners L P/il | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By Business Wire Business Wire • 01-19-2023
By Business Wire Business Wire • 06-08-2023
By Business Wire Business Wire • 12-19-2022
By GuruFocus Research • 11-09-2023
By Business Wire Business Wire • 02-02-2023
By Business Wire Business Wire • 06-01-2022
By Business Wire Business Wire • 06-07-2023
By Business Wire • 01-08-2024
By Business Wire Business Wire • 02-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.